RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/22787119http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/22787119http://www.w3.org/2000/01/rdf-schema#comment"The TGF-β pathway is under active consideration as a cancer drug target based on its capacity to promote cancer cell invasion and to create a protumorigenic microenvironment. However, the clinical application of TGF-β inhibitors remains uncertain as genetic studies show a tumor suppressor function of TGF-β in pancreatic cancer and other epithelial malignancies. Here, we used genetically engineered mouse models to investigate the therapeutic impact of global TGF-β inhibition in pancreatic cancer in relation to tumor stage, genetic profile, and concurrent chemotherapy. We found that αvβ6 integrin acted as a key upstream activator of TGF-β in evolving pancreatic cancers. In addition, TGF-β or αvβ6 blockade increased tumor cell proliferation and accelerated both early and later disease stages. These effects were dependent on the presence of Smad4, a central mediator of TGF-β signaling. Therefore, our findings indicate that αvβ6 and TGF-β act in a common tumor suppressor pathway whose pharmacologic inactivation promotes pancreatic cancer progression."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.org/dc/terms/identifier"doi:10.1158/0008-5472.can-12-0634"xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Bardeesy N."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Deshpande V."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Harper J."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Zimmerman S.M."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"O'Dell M.R."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Brekken R.A."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Hezel A.F."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Contino G."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Lonning S."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Rivera L.B."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/author"Alagesan B."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/date"2012"xsd:gYear
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/name"Cancer Res"xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/pages"4840-4845"xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/title"TGF-beta and alphavbeta6 integrin act in a common pathway to suppress pancreatic cancer progression."xsd:string
http://purl.uniprot.org/citations/22787119http://purl.uniprot.org/core/volume"72"xsd:string
http://purl.uniprot.org/citations/22787119http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/22787119
http://purl.uniprot.org/citations/22787119http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/22787119
http://purl.uniprot.org/uniprot/#_A0A078BBI5-mappedCitation-22787119http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/22787119
http://purl.uniprot.org/uniprot/#_A0A078BC11-mappedCitation-22787119http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/22787119
http://purl.uniprot.org/uniprot/#_A0A087WXP3-mappedCitation-22787119http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/22787119
http://purl.uniprot.org/uniprot/#_A0A078BCJ0-mappedCitation-22787119http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/22787119